On this page
Dementia is the condition where families are most willing to try anything, which is exactly why the claims made about it need the closest reading. Stem cell therapy for Alzheimer’s disease has one randomised phase 2a trial behind it, and a second study that found the cells provoked inflammation in the brain rather than calming it.
The randomised trial
A phase 2a randomised controlled trial tested an allogeneic cell product in mild Alzheimer’s disease — Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial.
Phase 2a means early: small, primarily concerned with safety and signal, and designed to decide whether a larger trial is worth running rather than to establish benefit.
Mild disease also matters. The trial did not recruit people with advanced dementia, and its results say nothing about that group — which is the group most often brought to clinics abroad.
The finding nobody quotes
A study of cells delivered directly into the brain’s fluid spaces reported a specific inflammatory response — Intracerebroventricular human mesenchymal stem cells induce MMP9-driven transient inflammation in Alzheimer’s disease.
Cells introduced into the brain provoked inflammation there. The paper describes it as transient, and it is still the opposite of the anti-inflammatory effect usually given as the rationale.
Results like this are why direct brain delivery is confined to research settings with monitoring. They are also never mentioned in marketing material, which tells you something about how that material is assembled.
Why dementia resists this approach
By the time Alzheimer’s is diagnosed, substantial numbers of neurons and their connections are already lost. Neurons are not readily replaced, and the connections between them encode a lifetime of learning that no transplant reconstructs.
The blood-brain barrier also blocks most of what is infused intravenously. Very few cells reach brain tissue, which limits any claimed mechanism that depends on their being there.
Vascular dementia, mixed dementia and Lewy body dementia are different diseases with different pathology. They are frequently lumped together in marketing, and no cell therapy trial has addressed them separately.
What improvement would even mean
Cognitive testing is noisy. Performance varies with sleep, mood, infection, medication, time of day and practice at the test itself.
A person tested twice, several months apart, in a hopeful family context, will often score better the second time for reasons unrelated to any treatment. Trials handle this with control groups and blinded assessors.
Families describing someone as “more themselves” after treatment are describing something real to them, and it is not evidence of an effect on the disease. Both of those statements are true at once.
What is actually available now
Cholinesterase inhibitors and memantine have modest effects on symptoms with established evidence.
Anti-amyloid antibodies have shown measurable slowing of decline in large randomised trials in early disease, with significant side-effect profiles requiring MRI monitoring, and access varies by country.
Treatment of hearing loss, depression, sleep disturbance and cardiovascular risk factors has real effects on function and is frequently neglected while more exotic options are pursued.
Occupational therapy assessment of the home, and planning for care needs before a crisis forces it, change outcomes for both the person and the family more than anything discussed on this page.
The limits of current evidence sets out why the gap between these options and what is marketed is as wide as it is.
Where the research is actually heading
The serious effort in dementia is not about infusions. It is about identifying the disease a decade before symptoms appear, using blood tests for amyloid and tau that have improved sharply, and intervening while neurons are still there to protect.
Prevention research has also produced results worth acting on. Controlling blood pressure in midlife, treating hearing loss, staying physically active, avoiding head injury and managing diabetes are each associated with reduced dementia risk across large population studies.
A substantial share of dementia risk across a population is attributable to factors of that kind. Those are not exciting interventions and they are the ones supported by evidence — type 2 diabetes is one of them, and it is covered here for that reason.
Someone looking for something to do about dementia risk in their family has real options. None of them involves a flight.
The economics of desperation
Dementia produces a family willing to spend a great deal, a patient who often cannot consent meaningfully, and a condition with fluctuations that make any intervention look effective for a while.
Those three facts together describe the single most exploitable situation in medicine, and the sector reflects it.
A clinic that declines to treat advanced dementia is telling you something useful about how it operates. This site sets out where that line is drawn here.
Consent
Someone with moderate or advanced dementia may not be able to weigh the information needed to consent to an experimental treatment involving international travel.
That is a serious matter, not a formality. Travel itself is disorienting for people with dementia and can precipitate a lasting decline in function.
Any proposal should address who is consenting, on what basis, and what happens if the patient becomes distressed or unwell abroad.
Questions worth asking
- Which trial supports this, at what stage of disease?
- What did the study on direct brain delivery report?
- How will benefit be measured, by whom, and against what baseline?
- Has an anti-amyloid treatment been considered if the disease is early?
- Who is consenting, and how is that being handled?
Cognitive decline covers the broader memory question, and the limits of current evidence sets out what remains unknown.
Frequently asked questions
Is there any trial in Alzheimer’s?
One randomised phase 2a trial in mild disease. Phase 2a is designed to decide whether a larger trial is worth running, not to establish benefit.
Can lost memory be restored?
No. Neurons are not readily replaced, and the connections between them encode a lifetime of learning that no transplant reconstructs.
Is there evidence of harm?
A study of cells delivered into the brain’s fluid spaces reported an inflammatory response there. It is described as transient, and it is not what the rationale predicts.
My relative seemed better afterwards. Does that count?
It is real to you and it is not evidence about the disease. Cognitive performance varies with sleep, mood, infection and practice at the test.
What about advanced dementia?
The trial recruited people with mild disease. Nothing in it speaks to advanced dementia, and travel itself can precipitate lasting decline.
Does it work for vascular dementia?
Vascular, mixed and Lewy body dementia are different diseases. No cell therapy trial has addressed them separately.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.